Nektar Therapeutics (NKTR) Receives Consensus Recommendation of “Buy” from Brokerages

Nektar Therapeutics (NKTR) Receives Consensus Recommendation of “Buy” from Brokerages

Nektar Therapeutics (NASDAQ:NKTR) has been assigned a consensus rating of “Buy” from the nine research firms that are covering the firm. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $21.17.

Several research analysts have commented on NKTR shares. Piper Jaffray Companies set a $25.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Saturday, October 1st. Jefferies Group LLC boosted their target price on shares of Nektar Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, November 7th. Brean Capital reissued a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research note on Friday, September 30th. Aegis started coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 8th. They set a “buy” rating and a $21.00 target price for the company. Finally, Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 29th.

In other news, CEO Howard W. Robin sold 93,458 shares of the company’s stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $13.88, for a total transaction of $1,297,197.04. Following the transaction, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 87,500 shares of the company’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $12.35, for a total transaction of $1,080,625.00. Following the transaction, the chief executive officer now owns 265,408 shares in the company, valued at approximately $3,277,788.80. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can boosted its position in shares of Nektar Therapeutics by 3.4% in the third quarter. Bank of Montreal Can now owns 6,395 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 208 shares during the period. Strs Ohio increased its position in shares of Nektar Therapeutics by 39.4% in the third quarter. Strs Ohio now owns 9,200 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 2,600 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Nektar Therapeutics during the third quarter valued at approximately $189,000. BlackRock Inc. increased its position in shares of Nektar Therapeutics by 29.6% in the second quarter. BlackRock Inc. now owns 11,681 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 2,668 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in shares of Nektar Therapeutics by 500.7% in the second quarter. Cubist Systematic Strategies LLC now owns 11,911 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 9,928 shares during the last quarter. Hedge funds and other institutional investors own 85.87% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) traded up 0.82% on Friday, reaching $12.35. 794,428 shares of the company traded hands. Nektar Therapeutics has a one year low of $10.52 and a one year high of $19.98. The company’s market capitalization is $1.89 billion. The stock’s 50 day moving average price is $12.67 and its 200 day moving average price is $15.11.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The firm had revenue of $36.30 million for the quarter, compared to analysts’ expectations of $32.42 million. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The company’s revenue for the quarter was down 39.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.06) earnings per share. On average, equities research analysts predict that Nektar Therapeutics will post ($1.07) EPS for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Related posts

Leave a Comment